Cor­rect­ed: Bay­er's Blue­Rock group moves Parkin­son's cell ther­a­py to PhII af­ter clear­ing ear­ly study

Bay­er’s Blue­Rock sub­sidiary says ear­ly da­ta sug­gest its stem cell ther­a­py is safe for pa­tients with Parkin­son’s dis­ease, of­fer­ing the first clin­i­cal proof-of-con­cept al­most four …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER